Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale CFO and Treasurer sold 1,448 shares at an average $74.68 ($108,135)
  2. 4 Open-market sale Chief Medical Officer sold 1,470 shares at an average $74.68 ($109,785)
  3. 4 Open-market sale President and CEO sold 5,112 shares at an average $73.79 ($377,211)
  4. 8-K/A Event Executive or director change
  5. SC 13G/A Stake Amended Statement of Ownership
  6. SC 13G/A Stake Amended Statement of Ownership
  7. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $67.84 ($678,361)
  8. 8-K Event Other events
  9. 4 Open-market sale President and CEO sold 18,334 shares at an average $68.44 ($1,254,819)
  10. SC 13G/A Stake Amended Statement of Ownership
  11. SC 13G Stake Amended Statement of Ownership
  12. 4 Open-market sale CFO and Treasurer sold 50,000 shares at an average $71.45 ($3,572,556)
  13. 4 Derivatives Options or other derivatives
  14. 3 Insider Initial Statement of Ownership
  15. SC 13G/A Stake Amended Statement of Ownership
  16. 8-K Event Executive or director change · Regulation FD disclosure
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Open-market sale COO and Secretary sold 70,000 shares at an average $74.95 ($5,246,408)
  20. 4 Open-market sale President and CEO sold 88,334 shares at an average $74.96 ($6,621,782)

Page 26 of 40 · 789 filings